SKYTROFA
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

SKYTROFA Trademark

Serial Number: 90154281 • Registration: 6459614

SKYTROFA is a trademark filed by Ascendis Pharma Endocrinology Division A/S on September 2, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Ascendis Pharma Endocrinology Division A/S (14 trademarks)

Hellerup 2900 , DK

Entity Type: 99

Trademark Details

Filing Date

September 2, 2020

Registration Date

August 24, 2021

Published for Opposition

June 8, 2021

Goods & Services

Medical devices for injection, dosage and control of pharmaceuticals, namely, medical devices for injection, dosage measurement and monitoring of pharmaceuticals for the treatment of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases; syringes for medical purposes and for injections; syringes for injection for medical and surgical use, namely, syringes in the form of pens for surgical use; digitally connected medical devices for monitoring the dispensation of pharmaceutical preparations for use in connection with management of growth hormone disorders, hypoparathyroidism, skeletal dysplasia, cancer and diabetes; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus for diagnostic purposes, namely, medicine dosage dispensers containing software featuring web-based medical information for physical and psychological examination and assessment of patients remotely and at a clinic; dosage management dispensers containing software for medical information management for guidance and control of medicines and for therapeutic use in web-based physical and psychological examination and assessment of patients remotely and at a clinic

Pharmaceutical preparations for the treatment of growth disorders, pharmaceutical preparations for the treatment of endocrine disorders, pharmaceutical preparations for the treatment of bone disorders, pharmaceutical preparations for the treatment of cancer, pharmaceutical preparations for the treatment infectious diseases; diagnostic preparations for medical use, namely, diagnostic preparations for identifying and detecting growth hormone deficiency, endocrine disorders, bone disorders, cancer, and infectious diseases

Downloadable computer software and downloadable computer programs for use in providing medical advice and advice on medications for treatment, patient assistance and health insurance in the field of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases; downloadable computer application software for mobile phones, tablet computers, handheld computers and personal computers, namely, a downloadable software application for sharing information related to growth disorders, endocrine disorders, bone disorders, cancer, infectious diseases and the treatment of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases for use by patients with growth hormone disorders, hypoparathyroidism, skeletal dysplasia, and diabetes in the medical field of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases; downloadable computer application software for mobile phones, tablet computers handheld computers and personal computers, namely, downloadable software that coordinates the delivery of health care services between health care providers, patients and those parties responsible for the payment of health care services, namely, downloadable software that allows individuals seeking medical education, information and services to locate a physician and treatment facility in their geographic area for medical treatment and allows physicians and health care professionals to communicate their credentials and specialization to patients and parties responsible for payment of healthcare services; downloadable computer application software for mobile phones, tablet computers, handheld computers and personal computers, namely, downloadable software that enables health care providers to monitor patients, communicate clinical information relevant to a patient's care, provide and exchange information concerning patients and the health care services provided to patients; downloadable software, downloadable software applications and downloadable mobile applications for providing co-pay and other financial or medical access support; downloadable computer software for providing a communications platform enabling users to share health and healthcare information; downloadable software, downloadable software applications and downloadable mobile applications for the measurement of height, weight, blood pressure, serum calcium, blood glucose, and heart rate; downloadable software, downloadable software applications and downloadable mobile applications for providing, exchanging, retrieving and analyzing health and healthcare information; downloadable software for medical purposes, namely, for formatting, viewing and transmitting medical data collected and stored on hormone injection pens and pumps and between said injection pens and pumps and portable electronic devices; downloadable computer application software for mobile phones, tablet computers, handheld computers and personal computers, namely, a downloadable software application for providing healthcare-related information, medication reminders, and tracking medication dosing history; the foregoing downloadable software related to pharmaceutical preparations for the treatment of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Aug 24, 2026 REM1
REGISTERED-PRINCIPAL REGISTER
Aug 24, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 8, 2021 NPUB
PUBLISHED FOR OPPOSITION
Jun 8, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 19, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 4, 2021 CNSA
ATTORNEY REVIEW COMPLETED
May 4, 2021 ATRV
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Feb 15, 2021 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 7, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 7, 2021 GNSL
SUSPENSION LETTER WRITTEN
Jan 7, 2021 CNSL
ASSIGNED TO EXAMINER
Jan 7, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 7, 2020 NWOS
NEW APPLICATION ENTERED
Sep 5, 2020 NWAP